User login
Key clinical point: The achievement of stringent treatment goals with secukinumab led to clinically meaningful benefits in physical function in patients with psoriatic arthritis (PsA), with secukinumab showing a protective effect on radiographic progression.
Major finding: Overall, over 2 years, a relatively small percentage of patients receiving secukinumab achieved sustained remission (REM) according to very low disease activity (LDA; 19%-24%) or Disease Activity index for PsA (DAPSA) REM (30%-36%), with those achieving DAPSA LDA+REM or DAPSA REM showing numerically greater improvement in physical function. A higher proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM.
Study details: This was a retrospective analysis from the FUTURE 5 study including 996 patients with active PsA who were randomly assigned to receive secukinumab or placebo.
Disclosures: This study was funded by Novartis Pharma AG. Two authors declared being employees of or owning stocks/shares in Novartis, and several authors reported ties with various sources, including Novartis.
Source: Coates LC et al. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: Results from the 2-year phase 3 FUTURE 5 study. RMD Open. 2023;9(2):e002939 (Apr 24). Doi: 10.1136/rmdopen-2022-002939
Key clinical point: The achievement of stringent treatment goals with secukinumab led to clinically meaningful benefits in physical function in patients with psoriatic arthritis (PsA), with secukinumab showing a protective effect on radiographic progression.
Major finding: Overall, over 2 years, a relatively small percentage of patients receiving secukinumab achieved sustained remission (REM) according to very low disease activity (LDA; 19%-24%) or Disease Activity index for PsA (DAPSA) REM (30%-36%), with those achieving DAPSA LDA+REM or DAPSA REM showing numerically greater improvement in physical function. A higher proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM.
Study details: This was a retrospective analysis from the FUTURE 5 study including 996 patients with active PsA who were randomly assigned to receive secukinumab or placebo.
Disclosures: This study was funded by Novartis Pharma AG. Two authors declared being employees of or owning stocks/shares in Novartis, and several authors reported ties with various sources, including Novartis.
Source: Coates LC et al. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: Results from the 2-year phase 3 FUTURE 5 study. RMD Open. 2023;9(2):e002939 (Apr 24). Doi: 10.1136/rmdopen-2022-002939
Key clinical point: The achievement of stringent treatment goals with secukinumab led to clinically meaningful benefits in physical function in patients with psoriatic arthritis (PsA), with secukinumab showing a protective effect on radiographic progression.
Major finding: Overall, over 2 years, a relatively small percentage of patients receiving secukinumab achieved sustained remission (REM) according to very low disease activity (LDA; 19%-24%) or Disease Activity index for PsA (DAPSA) REM (30%-36%), with those achieving DAPSA LDA+REM or DAPSA REM showing numerically greater improvement in physical function. A higher proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM.
Study details: This was a retrospective analysis from the FUTURE 5 study including 996 patients with active PsA who were randomly assigned to receive secukinumab or placebo.
Disclosures: This study was funded by Novartis Pharma AG. Two authors declared being employees of or owning stocks/shares in Novartis, and several authors reported ties with various sources, including Novartis.
Source: Coates LC et al. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: Results from the 2-year phase 3 FUTURE 5 study. RMD Open. 2023;9(2):e002939 (Apr 24). Doi: 10.1136/rmdopen-2022-002939